Translate this page into:
Early Stage of Tumour-Induced Osteomalacia
*Corresponding author: Dr. Srinivas Ananth Kumar, Department of Nuclear Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, India. srinivasananthk@gmail.com
-
Received: ,
Accepted: ,
How to cite this article: Kumar SA, Goyal H, Halanaik D. Early Stage of Tumour-Induced Osteomalacia. Indian J Nucl Med. 2026;41:273. doi: 10.25259/IJNM_80_2026
The patient had persistent hypophosphatemia with elevated serum fibroblast growth factor (FGF) 23 levels (100 pg/ml). 68Ga-DOTATATE PET/CT (Computed tomography) showed a somatostatin-receptor-expressing lesion in the cribriform plate and left sphenoethmoidal recess. Surgical excision of the lesion showed a spindle cell neoplasm, consistent with a phosphaturic mesenchymal tumour. Normal radiographs and dual-energy X-ray absorptiometry (DEXA) scan suggested early-stage disease without overt skeletal changes. This case highlights the utility of 68Ga-DOTATATE PET/CT in detecting tumour-induced osteomalacia even in the early stages when conventional imaging studies are negative.[1]
Author contributions:
SAK, HG and DH: Helped in the manuscript making process.
Ethical approval:
Institutional Review Board approval is not required.
Declaration of patient consent:
Patient's consent is not required, as the patient's identity is not disclosed or compromised.
Conflicts of interest:
There are no conflicts of interest.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation:
The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript, and no images were manipulated using AI.
Financial support and sponsorship: Nil.
References
- Silent scans, persistent pain: Unmasking a hidden culprit. Indian J Nucl Med. 2026;41:142.
- [CrossRef] [Google Scholar]